Why the study?
Does standardized clotting time provide a better guide for adjusting bishydroxycoumarin dosage compared to prothrombin activity in patients with cardiovascular diseases?
Does standardized clotting time provide a better guide for adjusting bishydroxycoumarin dosage compared to prothrombin activity in patients with cardiovascular diseases?
Standardized whole blood clotting time is a more reliable guide than prothrombin activity for adjusting bishydroxycoumarin dosage to prevent hemorrhagic complications.
May favor clotting-time monitoring over prothrombin activity for VKA dosing; leaves open randomized validation in contemporary practice.
• Standardized clotting time (method developed by the authors) and prothrombin activity were measured in 40 patients who were receiving bishydroxycoumarin in the treatment of cardiovascular diseases. The drug gave a reliable prolongation of the clotting time, and when the clotting time was kept within the therapeutic range there were neither thromboembolic complications nor hemorrhagic accidents. All hemorrhagic accidents occurred when the clotting time exceeded 22 minutes. The time relations and correlation coefficients for clotting time and prothrombin activity showed that these tests measure different phases of blood coagulation. The clotting-time test was the more valuable guide in adjusting dosages in anticoagulant therapy.
No takes yet. Share an insight, caveat, or question.
G Mayer (1956) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: